Moving Toward a Common Pathogenic Mechanism and Therapeutic Targets for APOL1 Nephropathies
- 28 February 2022
- journal article
- editorial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 79 (6) , 901-903
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (DK127638)
This publication has 12 references indexed in Scilit:
- Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodesJournal of Clinical Investigation, 2021
- Macrophage polarization in innate immune responses contributing to pathogenesis of chronic kidney diseaseBMC Nephrology, 2020
- Alterations in plasma membrane ion channel structures stimulate NLRP3 inflammasome activation in APOL1 risk milieuThe FEBS Journal, 2019
- APOL1 Nephropathy Risk Alleles and Risk of Sepsis in BlacksClinical Journal of the American Society of Nephrology, 2019
- Nucleosomal dsDNA Stimulates APOL1 Expression in Human Cultured Podocytes by Activating the cGAS/IFI16-STING Signaling PathwayScientific Reports, 2019
- Mitochondrial Damage and Activation of the STING Pathway Lead to Renal Inflammation and FibrosisCell Metabolism, 2019
- APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition PoreJournal of the American Society of Nephrology, 2019
- Deletion of the Mitochondrial Complex-IV Cofactor Heme A:Farnesyltransferase Causes Focal Segmental Glomerulosclerosis and Interferon ResponseThe American Journal of Pathology, 2018
- APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase RCommunications Biology, 2018
- Inflammasomes: mechanism of action, role in disease, and therapeuticsNature Medicine, 2015